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OpinionSchistosoma haematobium, a parasitic flatworm that
infects more than 100 million people, mostly in the
developing world, is the causative agent of urogenital
schistosomiasis, and is associated with a high incidence
of squamous cell carcinoma (SCC) of the bladder. Schis-
tosomiasis haematobia also appears to negatively influ-
ence fertility, and is particularly associated with female
infertility. Given that estrogens and estrogen receptors
are key players in human reproduction, we speculate
that schistosome estrogen-like molecules may contrib-
ute to infertility through hormonal imbalances. Here, we
review recent findings on the role of estrogens and
estrogen receptors on both carcinogenesis and infertility
associated with urogenital schistosomiasis and discuss
the basic hormonal mechanisms that might be common
in cancer and infertility.
The case of schistosomiasis
Schistosomiasis is a neglected tropical disease transmitted
to humans from freshwater snails. It is caused by a blood
fluke of the genus Schistosoma. Schistosomiasis is consid-
ered the most important of the helminthiases and the
second most important parasitosis, after malaria, causing
high rates of morbidity and mortality. Schistosomes affect
at least 76 countries and 200 million people worldwide.
From these, 20 million have severe disease and 120 million
are considered symptomatic. Risk of infection affects
600 million others including travelers from developed
countries [1].1471-4922/
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246 Trends in Parasitology, June 2015, Vol. 31, No. 6This opinion focuses on estrogen metabolism and estro-
gen receptor (ER) signaling pathways associated with
cancer induction and female infertility in the context of
Schistosoma haematobium infection. The present work
attempts to integrate a variety of studies and experimental
approaches with S. haematobium models, while giving
particular emphasis to the in vitro studies that have
contributed to expanding our understanding of the mech-
anisms of action of estrogen metabolism and ER signaling
pathways associated with schistosomiasis. In particular,
we suggest that hormonal imbalance resulting from
S. haematobium may promote cancer and infertility.
Urogenital schistosomiasis
Three major species of schistosomes are the agents of
human schistosomiasis – Schistosoma japonicum and
Schistosoma mansoni cause intestinal schistosomiasis in
East Asia, Africa, South America and the Caribbean, while
S. haematobium, occurring widely throughout Africa and
the Middle East, causes urogenital schistosomiasis. Recent
recalibration of health burdens revealed that in the range
of 4.5–70 million disability adjusted life years (DALYs)
are lost to schistosomiasis. More people are infected with
S. haematobium than with the other schistosomes com-
bined. Of 112 million cases of S. haematobium infection
in sub-Saharan Africa, 70 million are associated with
hematuria, 18 million with major bladder wall pathology,
and 10 million with hydronephrosis leading to kidney
damage [2–4]. In many patients, deposition of S. haema-
tobium parasite ova eventually leads to squamous cell
carcinoma (SCC) of the bladder [5,6]. Accordingly, S. hae-
matobium has been classified as a Group 1 carcinogen by
the International Agency for Research on Cancer (IARC)
[7,8]. In addition, as many as 75% of women infected with
S. haematobium suffer from female genital schistosomiasis
(FGS) of the lower genital tract [3]. FGS results from
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Figure 1. Comparison of the rat (r) ERa and rERb proteins and percent amino acid
homology in the functional regions (Adapted from [20]). Abbreviation: ER, estrogen
receptor.
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na, and/or vulva, with ensuing inflammatory responses;
it also increases susceptibility of the woman to HIV
[9–11]. The resulting FGS is associated with contact bleed-
ing, discharge, pain on intercourse, as well as diminished
fertility, besides being a source of shame and stigma [12].
The cellular and molecular mechanisms linking
S. haematobium infection either with both cancer induc-
tion and female infertility remain to be deciphered
[12,13]. However, estrogen-derived molecules and estrogen
receptor signaling pathways have been described for both
associations. Accordingly, we review and discuss the gen-
eral molecular mechanisms underlying estrogen metabo-
lism, focusing on the hormones and receptors involved.
Molecular mechanism underlying estrogen metabolism
Estrogens are steroid hormones produced in the ovaries,
adrenal glands, and placenta during pregnancy. The
hypothalamus secretes gonadotropin-releasing hormone
(GnRH), which stimulates the anterior pituitary to release
follicle-stimulating hormone (FSH) and luteinizing
hormone (LH). FSH and LH induce the production of estro-
gen in the form of estradiol and estrone by the ovaries. These
estrogens bind to ERs in target tissues of the breast, uterus,
brain, bone, liver, and heart [14]. When the estrogen mole-
cule binds to its receptor, a conformational change in the ER
permits its interaction with a specific regulatory sequence of
the ER gene (estrogen responsive element), inducing the
transcription of this target coding sequence. The resulting
ER protein promotes changes in the cell according to tissue
type and underlying conditions. The cycle is completed when
high levels of estrogen in the blood send negative feedback to
the hypothalamus to suppress the release of GnRH [14].
By the 1950s, most of the basic actions of the estrogenic
hormones were recognized, such as their stimulation on the
growth and function of tissues of the female reproductive
tract. However, the biochemical processes involved were not
entirely clear [15]. The generally accepted hypothesis was
that the 17-hydroxyl group of estradiol underwent enzymat-
ic oxidation from a cholesterol molecule using one coenzyme
(NADH), and the resulting estrone was reduced using
another (NADPH) [15]. The identification of the ER provided
a mechanism to describe the target site specificity of
estrogen action in the uterus, vagina, pituitary gland, and
breast tissue [16]. Most importantly, a test was established
to predict the outcome of antihormonal therapy in breast
cancer, and a target was identified to develop new drugs for
the treatment and prevention of breast cancer [16].
ERs and action of estrogen
Nuclear hormone receptors belong to a family of hormone-
activated transcription factors that can initiate or enhance
the transcription of genes containing specific hormone
response elements [17]. The human ER, which belongs
to this family, was cloned and sequenced from MCF-7
human breast cancer cells [17]. The human ER locus is
located on chromosome 6q sub-band 25.1 [18] and the
mouse ER is located on chromosome 10 [19,20]. The ER
consists of 595 amino acids with a molecular mass of
66 kDa and includes six functional domains [20–22]; two
of the domains are highly conserved among the members ofthe nuclear hormone receptor superfamily [20–22]. Two
zinc fingers at the DNA-binding domain (DBD) of ER
mediate receptor binding to hormone-response elements
in the promoter regions of hormone-responsive genes. The
hormone-binding domain (HBD), located at the ER C
terminus, exhibits two regions of sequence homology with
other hormone receptors. These regions confer hormone
specificity and selectivity to ER [22–26].
More recently, another sequence belonging to the
nuclear hormone receptor superfamily was cloned from a
rat prostate cDNA library [27,28]. This sequence was
named ERb (as opposed to ERa). ERb contains 485 amino
acid residues and has a molecular weight of 54.2 kDa
(Figure 1). There is a high homology between ERa and
ERb, mainly in the DBD (95%) and the HBD (55%), and
both proteins bind estrogen with high affinity, bestowing
functional homology. The latter has been determined by
the activation of transcription of a vitellogenin A2, an
estrogen-response element (ERE)-containing reporter
plasmid in the presence and absence of estrogen [20,27].
The mechanism of target site specificity and selectivity
seen with anti-estrogens, such as raloxifene, could be
explained by the existence of two different ERs [29]. The
receptor-specific regions are probably responsible for the
differences seen between ERa and ERb, in spite of the high
homology in the conserved regions of both ERs [20].
Estrogen diffuses through the plasma membrane of cells
where it binds to the ER. Once estrogen binds to the
inactive ER, the receptor is activated, a conformational
change and homodimerization occurs, and two receptor–
ligand monomers dimerize and bind to the ERE. Once
bound to the ERE, the ER uses activation functions
(AFs) (AF-1 and AF-2) to stimulate transcription from247
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main areas called AFs: AF-1 is located in the N-terminal
region of the ER and AF-2 is located in the C-terminal region
in the ligand-binding domain (LBD) of the ER. These are
synergistic when the ER is activated by estrogen. Using
mammalian cells, it was shown that the AF-1 and AF-2
regions, when expressed as separate polypeptides, function-
ally interact in response to estrogen and anti-estrogens,
thus suggesting that estrogen binding to the ER facilitates
a conformational change that brings AF-1 and AF-2 in direct
association with one another, leading to synergy that results
in transcriptional activation. These findings explained
mechanistically the role of the two AFs in mediating hor-
mone-regulated transcription [20,28]. The EREs are consti-
tuted by 13-bp palindromic sequences upstream the
transcriptional start site. Binding of the ER to the corre-
sponding ERE enhances the transcriptional rate of the gene
in the target tissue, for example, breast [20,30].
ER mediates the biological effects of estrogens in a
variety of target tissues. Ligand binding to ER stimulates
gene transcription via interaction with EREs. ERs are
known to mediate important physiological functions, such
as reproduction, metabolism, maintenance of bone density
and growth of estrogen-responsive tumors, including
breast and endometrial cancers. Estrogens are also known
to have a mitogenic effect in estrogen-responsive cells
[31]. Progress in the regulation of the ER in breast cancer
and anti-estrogen therapy has been reviewed [20].
S. haematobium-associated bladder cancer
SCC is a malignant, poorly differentiated neoplasm. SCC
is the common form of bladder cancer in rural Africa where
S. haematobium is prevalent [32,33]. By contrast, the
majority of bladder cancer in developing countries and
regions not endemic for urogenital schistosomiasis is
transitional cell carcinoma (TCC), which arises from the
transitional epithelium lining of the bladder. The parasite
eggs trapped in the bladder wall release antigens and other
metabolites (presumably evolved to expedite egress to
the urine, and hence to the external environment). The
phenomenon leads to hematuria and to chronic inflamma-
tion, in turn increasing the risk of SCC of the bladder. The
epidemiological association between SCC of the bladder
with schistosomiasis haematobia is based both on case
control studies and on the correlation of bladder cancer
incidence with prevalence of S. haematobium infection
within diverse geographic locations. The incidence of
urogenital schistosomiasis-associated SCC is estimated
in 3–4 cases per 100 000 [34]. Schistosomiasis haematobia
is a chronic infection. The adult, egg-producing schisto-
somes live for many years, re-infections frequently occur,
and schistosomiasis associated bladder SCC appears rela-
tively early, often by the mid-decades of life (TCC usually
presents in the later decades of life). In its recent mono-
graph, IARC confirmed that chronic infection with
S. haematobium causes cancer of the urinary bladder [8].
While addressing schistosomiasis-induced hypogonad-
ism in patients infected with S. haematobium and
S. mansoni, Botelho et al. observed a noteworthy elevation
in serum levels of estradiol, whereas those of LH and FSH
remained normal, and hypothesized that the excess248estradiol could be external to the host [13]. In fact, we
found that the molecule responsible for the effect was an S.
haematobium-derived estradiol-like molecule that is an
antagonist of estradiol and thus repressed the transcrip-
tional activity of the ER. Moreover, new estrogenic mole-
cules were identified in S. haematobium total antigen as
well as in the serum of infected individuals with this
parasitic disease that seem to be produced by this parasite
[35]. ER transcriptional activity was suppressed in urothe-
lial cells and ER expression was also suppressed in the
bladders of mice in response to S. haematobium [36].
Estrogenic molecules present in the egg extract of S.
haematobium were also identified and characterized by
liquid chromatography-mass spectroscopy (LC-MS). The
majority of these compounds are catechol estrogens
[1]. Catechol estrogens are formed by hydroxylation on
the steroid aromatic ring A. Hydroxylation of both C-2
and C-3 on a steroid ring was apparent and suffered
further oxidation into an estradiol-2,3-quinone. The geno-
toxic effects of estrogen metabolites might be attributed to
oxidation of catechol estrogens to quinones, followed by
redox cycling and formation of reactive oxygen species that
in turn react with DNA [37,38] (Figure 2).
Given the context of the unarguable link between
S. haematobium infection and bladder cancer, the pres-
ence of putative carcinogenic molecules in S. haemato-
bium eggs hopefully may have practical consequences
for new approaches to disease control [1,35]. Metabolism
of estrogens and the production of depurinating
estrogen–DNA adducts can be implicated in a pathway
underlying S. haematobium-promoted host cell DNA
damage, leading eventually to cell transformation.
The carcinogenic effect of this estrogen–DNA adduct-
mediated pathway could explain the link between chron-
ic schistosomiasis haematobia and SCC of the bladder
[1]. We anticipate that these findings will contribute
to understanding how schistosomiasis haematobia leads
to SCC of the bladder.
Schistosoma haematobium and infertility
Infertility is a common medical condition, affecting one in
six couples (15–20%) worldwide [39]. Human and animal
models have unraveled an association between estrogen
insufficiency with abnormal spermatogenesis and male
infertility [40–42]. Animal models reveal that ERa knock-
out (ERaKO) and double ERa/ERb knockout (ERa/bKO)
mice are infertile from puberty, and display atrophy of the
testes and seminiferous tubule dysmorphogenesis, likely to
lead to decreased spermatogenesis and sperm motility [43].
By contrast, ERb knockout (ERbKO) mice are fertile and
have no apparent reproductive alterations or morphologic
changes [40,43].
Hormonal disturbances in women with FGS may be
linked to infertility and suboptimal fecundity [11,44].
Recently, estrogen-like metabolites were detected by
LC–MS in urine of S. haematobium-infected women. These
metabolites are similar to those identified previously in
the adult worm and egg stages of S. haematobium
[1]. The presence of estrogen-like metabolites during FGS
was statistically associated with self-reported infertility
[11]. These electrophilic compounds can react with DNA
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Figure 2. Major metabolic pathways in cancer initiation influenced by estrogens. The formation of catechol estrogens, that is, 2-hydroxy(OH)E1(E2) and 4-OHE1(E2) can
lead through oxidation to semiquinones and quinones, for example, E1(E2)-3,4Q that eventually react with DNA to form depurinating adducts. Error-prone repair of the
apurinic sites may lead to mutations that can initiate bladder carcinoma with squamous differentiation (microphotograph). (Adapted from [40]).
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apurinic sites in chromosomal DNA that result from this
reaction generate mutations that might underlie infertility
[11,44].
Concluding remarks and future perspectives
Studies are necessary to identify and characterize
production of these estradiol-like moieties in schisto-
somes and ascertain the functions of the hormone in
the developmental cycle of the blood fluke. Indeed, block-
ing the binding of this molecule to its receptor, with the
use of antihormonal therapy such as ICI 182,780, a potent
anti-estrogen with the ability to inhibit and downregulate
ER [45], could be explored as a complementary therapy to
schistosomiasis.
A functional estrogen transmembrane receptor, G pro-
tein-coupled receptor (GPR)30, modulates both rapid non-
genomic events and genomic transcriptional events of
estrogen. GPR30 promotes the progress of estrogen-related
tumors through mitogen-activated protein kinase (MAPK)
signaling pathways. Effects mediated by GPR30 are main-
tained when classic ERs are absent or blocked. In addition,
GPR30 is involved in drug resistance, which is often occur-
ring during cancer treatment. Hence, simultaneous block-
ing both GPR30 and classic ERs may be a better strategy
for the treatment of schistosomiasis-related cancer and
infertility [46].
It will be informative to assess the specific effects of the
estrogenic molecules identified in the lysates of schisto-
somes and to evaluate activities of specific catechol estro-
gens identified in the schistosome eggs, either by using
catechol estrogens purified from eggs of S. haematobium
and/or synthetic versions of these putative carcinogens. In
addition, given that the genome and transcriptome of eggs,
female and male adult worms of S. haematobium areavailable, studies utilizing RNAi to silence components
of estrogen catabolism pathways such as schistosome
estradiol 17-b dehydrogenase and other candidate genes
should be informative [47–49].
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